Enable job alerts via email!
A diagnostics solutions company in Royston is seeking a Quality Control Scientist to ensure the quality of reagents in lab settings. This role involves running QC tests with qPCR, collaborating across teams, and maintaining documentation standards, making it ideal for detail-oriented scientists eager to impact healthcare outcomes.
Social network you want to login/join with:
Are you the kind of scientist who notices the details others miss? Good, we’ve got just the role for you.
At LEX Diagnostics, we’re on a mission to make diagnostics faster, simpler, and more accessible, without compromising performance. Our LEX VELO point-of-care PCR system is built to bring lab-quality results wherever they're needed. And behind every accurate test result is a set of reagents that have passed the highest standards of quality control.
That’s where you come in.
We’re looking for a Quality Control Scientist to join our Reagent Production team and take on a hands-on role assessing the consistency and quality of our reagents, from raw materials to final products. You’ll be running RT-qPCR assays, troubleshooting issues, collaborating across teams, and documenting results in a way that makes regulators smile.
If you’re comfortable in the lab, curious about how things work (or don’t), and excited to play a key role in getting a new IVD to market, we’d love to talk.
What you’ll be doing
Requirements
What we’re looking for
Nice to have
Our working culture encourages entrepreneurship, shared ideas, and technical collaboration, while providing you the freedom to do your best work. We also offer fantastic employee benefits including:
You’ll be part of brilliant team of scientists and engineers, in a culture that encourages ownership, curiosity, and collaboration.
You’ll also get:
Who are we and what does the future hold for you?
LEX Diagnostics was founded in 2020. Our innovative system integrates effortlessly into primary care settings, bringing PCR-level sensitivity to urgent care centres, physicians, labs, and pharmacies, all at a significantly lower cost per test than other molecular platforms.
2025 is a milestone year for us as we’ve just submitted dual 510(k) CLIA waiver applications to the U.S. FDA. This means you will be an important part of a high impact launch that will enhance your future career credentials.
The Future
In December 2023, QuidelOrtho invested in LEX Diagnostics, which included the exclusive option to acquire the company up to or shortly after 510(k) clearance by the FDA. In QuidelOrtho, we have an investment partner that recognises the capabilities of our team, and are excited for what we can continue to build together... We are optimistic to receive 510(k) clearance in late 2025 or early 2026.
What this means for you
2026 should see the elevation of the LEX Diagnostics team from startup environment into a well-supported, international diagnostics powerhouse without sacrificing the very thing that made our team successful, innovation. You’ll help drive forward a unique, market-leading platform within a growing team that needs to invest in your development and career growth.
Into the details, but ready for the bigger picture?
Come help us build something extraordinary. We’d love to hear from you.